ASTHMA

Study of Acid Reflux in Children with Asthma (SARCA)

Primary Investigator:  Charles Irvin, Ph.D., Director, Vermont Lung Center

Coordinator: Stephanie Burns

Who:   Children age 6-17 with asthma who do not have heartburn

What:  9 visits over 7 months

Compensation:  up to $550

Methacholine Bronchoprovocation – Influence of High Potency Corticosteroids in Asthma Study (MeCIS)

Primary Investigator:  Charles Irvin, Ph.D., Director, Vermont Lung Center

Coordinator: Stephanie Burns

Who: Children aged 12-17 and Adults with and without asthma

What: Nonasthmatics: 1 visit

           Asthmatics: 5 Visits over 16 weeks

Compensation: $50 per visit

Novel Application of the Forced Oscillation Technique in Subjects with Asthma

Primary Investigator:  David Kaminsky, M.D.

Coordinator:  Laurianne Griffes

Who:    People with stable asthma, moderate to severe asthma and people without asthma

What:   Up to 2 visits, each lasting about 1.5 hours

Compensation: up to $100

Idiopathic PuLMONARY Fibrosis (IPF)

Centocor CNTO888PUL2001: A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 888 Adminitered Intravenously in Subjects with Idiopathic Pulmonary Fibrosis

Primary Investigator: Yolanda Mageto, M.D.

Coordinator: Stephanie Burns

Who: People with Idiopathic Pulmonary Fibrosis

What: IV infusions every 4 weeks for 48 weeks, 3 follow up visits through week 72.

Compensation: $30 per visit.

CYSTIC FIBROSIS

A randomized, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 µg and 5 µg) administered once daily via the Respimat® device for 12 weeks in patients with cystic fibrosis.

Primary Investigator:  Laurie Whittaker, M.D.

Coordinator: Joan Lippmann

Who: People with Cystic Fibrosis

What: 8 visits over 12 weeks

Compensation: Up to $800.

Vertex: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy ofVX-770 in Subjects Aged 12 Years and Older With CysticFibrosis who are Homozygous for the F508del-CFTR Mutation

Primary Investigator:  Laurie Whittaker, M.D.

Coordinator: Joan Lippmann

Who: People with Cystic Fibrosis

What: 7 visits and 4 phone calls over 2 years

Compensation: Up to $950

GSK: A Randomized, Double Blind, Parallel Group, Placebo Controlled 28 Day Study to Investigate the Safety, Tolerability and Pharmacodynamics of SB-656933 in Patients with Cystic Fibrosis.

Primary Investigator:  Laurie Whittaker, M.D.

Coordinator: Joan Lippmann

Who: People with Cystic Fibrosis

What: 7 visits over 70 days

Compensation: Up to $650

SARCOIDOSIS

A Phase 2, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Evaluating the Safety and Efficacy of Treatment with Ustekinumab or Golimumab in Subjects with Chronic Sarcoidosis

Primary Investigator: Gerald Davis, M.D.

Coordinator: Laurianne Griffes

Who: People with Chronic Sarcoidosis

What:  Subcutaneous injections; 15 visits over 44 weeks

Compensation: $35 per visit